ArticleInternational journal of medical sciences2006
Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A.
Article in International journal of medical sciences, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Effects of CYP2C19 genetic polymorphisms on the cure rates ofFrontiers in pharmacology · 2022Pooled it
- Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.Gastroenterology · 2021Pooled it
- Helicobacter pylori eradication: influence of interleukin-1beta -31 C/T polymorphism.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesTrial
- Clinical significance of genetic polymorphisms of interleukin-1β and cytochrome P450 2C19 on the eradication ofNew microbes and new infections · 2023Article
- Association of specific haplotype of tumor necrosis factor-α and interleukin-1β polymorphisms withGerms · 2021Article
- Supplementation of Saponins from Leaves ofAntioxidants (Basel, Switzerland) · 2019Article
- Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2014Article
- Association between TNF-α and IL-1β genotypes vs Helicobacter pylori infection in Indonesia.World journal of gastroenterology · 2013Article
- Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.Nagoya journal of medical science · 2012Article
- Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.Nagoya journal of medical science · 2011Article
- Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.Journal of gastroenterology and hepatology · 2009Review
- Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation.Bone marrow transplantation · 2007Article
- Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.Archivum immunologiae et therapiae experimentalisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including lansoprazole.
methodsThis study examined the eradication rate among 67 participants in the polymorphism study who visited Daiko Medical Center, Nagoya University from July 2004 to October 2005. The participants aged 20 to 69 years were classified into three group according to CYP2C19 genotype; rapid metabolizers (RM) with *1*1 genotype, intermediate metabolizers (IM) with *1*2 or *1*3 genotype, and poor metabolizers (PM) with *2*2, *2*3, or *3*3 genotype. For the genotype classification, G681A (681G for *1 and 681A for *2) and G636A (636G for *1 and 636A for *3) were genotyped by PCR with confronting two-pair primers (PCR-CTPP). They were also genotyped for IL-1B T-31C and TNF-A T-1031C by a duplex PCR-CTPP.
resultsThe eradication rate was 70.0% for RM, 93.9% for IM, and 85.7% for PM. The difference in the rate between RM and IM+PM was statistically significant (p=0.025). The eradication rate was highest for those with IL-1B -31CC; the p value was marginal among the whole subjects (chi2=3.78, p=0.05) and not significant among the RM group (chi2=1.60, p=0.21). The genotypes of TNF-A T-1031C had no associations with the eradication rate. But among the RM group, the odd ratio (OR) of the TNF-A CT for the eradication rate relative to TT was marginally reduced (OR=0.05, 95% confidence interval, 0.002-1.19).
conclusionsThe present study confirmed the low eradication rate for RM. The reproduced finding provides evidence that the CYP2C19 genotype is useful to predict the success of the treatment. For the RM group, alternative regimens expected to be with a higher eradication rate will be recommended, especially to those with the TNF-A -1031C allele.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.